UNC13B Antibody, FITC conjugated
Description
Antibody Structure and Target Specificity
The UNC13B Antibody, FITC conjugated, is a rabbit polyclonal antibody targeting specific regions of the human UNC13B protein. Key structural features include:
Research Applications
This antibody is optimized for fluorescence-based techniques, enabling precise localization and quantification of UNC13B in cellular and tissue samples:
Key Applications
-
Immunofluorescence (IF)/Immunocytochemistry (ICC): Detects UNC13B in vesicles and Golgi apparatus (recommended concentration: 0.25–2 µg/ml) .
-
Flow Cytometry (FACS): Quantifies UNC13B expression in cell populations .
-
Immunohistochemistry (IHC): Highlights cytoplasmic and membranous staining in renal tubules (1:500–1:1000 dilution) .
Performance Highlights
-
Sensitivity: Shows strong positivity in Wilms’ tumor cells compared to normal renal cells .
-
Specificity: No cross-reactivity with unrelated epitopes confirmed via knockout validation in some studies .
Dilution Guidelines
| Application | Recommended Dilution |
|---|---|
| Immunofluorescence | 1:50–1:200 |
| Western Blot (WB) | 1:500–1:2,000 |
| ELISA | Manufacturer-dependent |
Formulation and Stability
-
Buffer: PBS (pH 7.2–7.4) with 40–50% glycerol for cryoprotection .
-
Shelf Life: Stable for ≥1 year at -20°C; avoid freeze-thaw cycles .
Role in Cancer Biology
-
Wilms’ Tumor: Elevated UNC13B expression correlates with lysosome-mediated resistance to doxorubicin. Knockdown increases apoptosis and drug sensitivity .
-
Mechanistic Insight: UNC13B regulates vesicle fusion and lysosomal activity, potentially influencing autophagy and drug sequestration .
Neuroscience Applications
-
Synaptic Function: UNC13B collaborates with UNC13A to control neurotransmitter release via synaptic vesicle priming .
Limitations and Considerations
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- A rare missense variation (V1525M) in UNC13B was identified through whole exome sequencing (WES) in a multiplex family. This variation was observed in five of six affected individuals but not in eight unaffected individuals or one individual with unknown disease status. Resequencing of UNC13B coding regions revealed five additional rare missense variations (T103M, M813T, P1349T, I1362T, and V1525M). PMID: 26990377
- The 1-5-8-26 CaM binding motif identified in Munc13-1 cannot be induced in the classical CaM target skMLCK, highlighting unique features of the Munc13 CaM binding motif. PMID: 24854537
- Munc13-1 regulates insulin exocytosis. PMID: 12871971
- Mutations in MUNC13-4 contribute to the development of familial haemophagocytic lymphohistiocytosis subtype 3 through a defective cytotoxic pathway. PMID: 15466010
- Research suggests that diacylglycerol-activated hmunc13 functions as an effector of Rab34, mediating lysosome-Golgi trafficking. PMID: 16138900
- A polymorphism in the UNC13B gene has been linked to nephropathy. UNC13B mediates apoptosis in glomerular cells in the presence of hyperglycemia, an early event in the development of nephropathy. PMID: 18633107
- In the bound state, the hydrophobic anchor residue of the calmodulin (CaM)-binding motif in Munc13 interacts with two distinct methionine residues in the carboxyl-terminal domain of CaM. PMID: 19492809
- The mechanistic basis for high glucose-induced protein secretion involves the interaction of munc13 and rab34, suggesting a potentially critical role for this pathway in the pathogenesis of diabetic nephropathy (DN). PMID: 19641095
